Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | March 01, 2023 | March 03, 2023 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | June 22, 2023 | June 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2033-02-28 | Direct | 28,000 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date.
SYNLOGIC, INC.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-22 | Direct | 30,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2023 Filed Jun 26, 2023 18:21 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-23-029804 · ownership.xml · derivative · entry 1 Kelly-Croswell Lisa · CIK 0001845596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:49 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001140361-23-010159 · form4.xml · derivative · entry 1 Kelly-Croswell Lisa · CIK 0001845596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2033-02-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 1, 2023, subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| July 18, 2022 Filed Jul 19, 2022 19:02 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001567619-22-014201 · doc1.xml · derivative · entry 1 Kelly-Croswell Lisa · CIK 0001845596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-07-17 F1 · derivative.exercise_date: The option vests in equal monthly installments over 36 months measured from July 18, 2022 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:15 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0000899243-22-022175 · doc4.xml · derivative · entry 1 Kelly-Croswell Lisa · CIK 0001845596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:11 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0000899243-21-023609 · doc4.xml · derivative · entry 1 Kelly-Croswell Lisa · CIK 0001845596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:10 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0000899243-21-005927 · doc4.xml · derivative · entry 1 Kelly-Croswell Lisa · CIK 0001845596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.